Stellar Biotechnologies Exceeds Aquaculture Capacity Goals
Stellar Biotechnologies, Inc. has announced that the Company exceeded its 2012 plan to increase key stages of its aquaculture capacity to prepare for future demand for Keyhole Limpet Hemocyanin (KLH).
For the year ending 2012, Stellar exceeded its aquaculture hatchery goal by nearly 30%, the combined result of expanded facilities and new methods related to the cultivation of the Giant Keyhole Limpet (Megathura crenulata).
The Giant Keyhole Limpet is a scarce sea mollusk and the sole source for KLH, a vitally important, immune-stimulating protein.
Following expansion of Stellar’s physical plant in 2011, the Company developed new and proprietary methods for cultivating limpets that ensures unprecedented survival rates of this important natural resource.
Stellar’s hatchery innovations and controlled conditions have optimized the Company’s production; increasing yields and setting the stage for long-term KLH capacity while reducing environmental impact.
The net result, given sufficient funding, is to accelerate Stellar’s projected KLH production capacity to as much as 5 kilograms per year within the next four years, to 20 kilograms per year a few years later.
“This positions Stellar as the only company that will be capable of supplying GMP grade KLH that can meet the anticipated long-term demand within the pharmaceutical industry,” said Frank Oakes, President and CEO. “This is a testament to our customer focus and operational excellence.”
“Exceeding aquaculture capacity ahead of schedule means we will be prepared to ensure scalable supplies of the highest quality KLH for our pharmaceutical partners,” said Brandon Lincicum, Stellar Executive Director of Aquaculture.